Sera Prognostics (NASDAQ:SERA) Insider Tiffany Eul Davis Inglis Sells 8,024 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Tiffany Eul Davis Inglis sold 8,024 shares of the stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $2.03, for a total transaction of $16,288.72. Following the sale, the insider directly owned 83,565 shares in the company, valued at $169,636.95. This represents a 8.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tiffany Eul Davis Inglis also recently made the following trade(s):

• On Thursday, September 10th, Tiffany Eul Davis Inglis sold 486 shares of Sera Prognostics stock. The shares were sold at an average price of $2.00, for a total transaction of $972.00.

Sera Prognostics Stock Performance

Shares of SERA stock opened at $2.04 on Wednesday. Sera Prognostics, Inc. has a fifty-two week low of $1.56 and a fifty-two week high of $3.95. The company has a 50 day moving average price of $2.04 and a 200 day moving average price of $2.02. The stock has a market capitalization of $80.48 million, a P/E ratio of -3.04 and a beta of 1.06.

Sera Prognostics (NASDAQ:SERA) last released its earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 47,475.72%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.07 million. On average, research analysts forecast that Sera Prognostics, Inc. will post -0.62 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings cut Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SERA. AWM Investment Company Inc. purchased a new stake in shares of Sera Prognostics in the 2nd quarter valued at approximately $377,000. Segall Bryant & Hamill LLC acquired a new stake in shares of Sera Prognostics in the 1st quarter valued at $193,000. Finally, Arkadios Wealth Advisors purchased a new stake in shares of Sera Prognostics during the 1st quarter worth $25,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a women’s health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company develops and commercializes blood tests designed to identify women at elevated risk for pregnancy complications, particularly spontaneous preterm birth.

Its lead product, the PreTRM Test, is a blood-based test that analyzes proteins associated with pregnancy and provides an individualized risk assessment for spontaneous preterm birth in singleton pregnancies.